公开(公告)号：US20240309079A1

公开(公告)日：2024-09-19

申请号：US18604466

申请日：2024-03-13

Applicant: TARAN THERAPEUTICS, INC. ,  THE UNIVERSITY OF ADELAIDE

Inventor： Cameron DURRANT ,  Daniel THOMAS ,  Dale CHAPPELL

IPC: C07K16/24 ,  A61K31/706 ,  A61K31/7072 ,  A61K39/00 ,  A61K39/395 ,  A61P35/02

CPC classification number: C07K16/243 ,  A61K31/706 ,  A61K31/7072 ,  A61K39/3955 ,  A61P35/02 ,  A61K2039/505 ,  A61K2039/54 ,  A61K2039/545 ,  C07K2317/21

Abstract: Provided herein are methods for treating a subject having chronic myelomonocytic leukemia (CMML), the method comprising: (a) identifying a RAS pathway mutation in tumor cells of the subject, wherein the RAS pathway mutation is a NRAS, KRAS, and/or CBL mutation; and (b) administering to the subject identified in step (a) a therapeutically effective amount of an anti-hGM-CSF antibody. The subject may have a RAS pathway mutation or a RAS pathway mutation and at least one TET2 mutation identified in the tumor cells. The methods further comprise administering a therapeutically effective amount of a hypomethylating agent. Also provided herein are methods for treating a subject having chronic myelomonocytic leukemia (CMML), the method comprising: (a) identifying a RAS pathway mutation in tumor cells of the subject, wherein the RAS pathway mutation is a NRAS, KRAS, and/or CBL mutation; and (b) administering to the subject identified in step (a) a therapeutically effective amount of an anti-hGM-CSF antibody lenzilumab and a therapeutically effective amount of a hypomethylating agent. The subject may have a RAS pathway mutation or a RAS pathway mutation and at least one TET2 mutation identified in the tumor cells. A therapeutically effective amount of a hypomethylating agent is further administered according to the provided methods.

公开(公告)号：US20250154243A1

公开(公告)日：2025-05-15

申请号：US18889359

申请日：2024-09-18

Applicant: TARAN THERAPEUTICS, INC. ,  THE UNIVERSITY OF ADELAIDE

Inventor： Cameron DURRANT ,  Daniel THOMAS

IPC: C07K16/24 ,  A61K31/17 ,  A61K31/706 ,  A61K31/7068 ,  A61K39/00 ,  A61K45/06 ,  A61P35/02 ,  C12Q1/6886

Abstract: Provided herein are methods for treating a subject having chronic myelomonocytic leukemia (CMML), the method comprising: (a) identifying a RAS pathway mutation in tumor cells of the subject, wherein the RAS pathway mutation is a NRAS, KRAS, PTPN-11 and/or CBL mutation; (b) identifying a dominant CBL mutation of CBL variant allele frequency of from 10%; and (c) administering to the subject identified in step (a) a therapeutically effective amount of an anti-hGM-CSF antibody. Also provided herein are methods for treating a subject having chronic myelomonocytic leukemia (CMML), the method comprising: (a) identifying a RAS pathway mutation in tumor cells of the subject, wherein the RAS pathway mutation is a NRAS, KRAS, PTPN-11 and/or CBL mutation; (b) identifying a dominant CBL mutation of CBL variant allele frequency of from 10%; and (c) administering to the subject identified in step (a) a therapeutically effective amount of an anti-hGM-CSF antibody lenzilumab and a therapeutically effective amount of a second therapeutic agent. The subject may have a RAS pathway mutation or a RAS pathway mutation and at least one TET2 mutation identified in the tumor cells, an increased percentage of CD116 and CD131 in CD34+ stem and progenitor cells in the subject compared to a healthy subject and/or an increased percentage of CD14+ cells in the subject compared to a healthy subject. A therapeutically effective amount of a hypomethylating agent or hydroxyurea may be further administered according to the provided methods.